VEGFR2 inhibition by shRNA or by apatinib, a small molecular tyrosine kinase inhibitor, reduced the osteosarcoma cell migration, invasion, and metastatic potential, and downregulated the STAT3 and RhoA/ROCK/LIMK2 pathways. This evidence concerns the gene KDR and osteosarcoma.